alog_pcfb.RdA dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo (Langford et al. 2016) . The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up in studies of at least 12 weeks follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.
alog_pcfbA data frame in long format (one row per arm and study), with 46 rows and 6 variables:
studyID Study identifiers
agent Character data indicating the agent to which participants were randomised
dose Numeric data indicating the standardised dose received
y Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm
se Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm
n Numeric data indicating the number of participants randomised
alog_pcfb is a data frame in long format (one row per arm and study), with the variables studyID, agent, dose, y, se, and N.
Langford O, Aronson JK, van Valkenhoef G, Stevens RJ (2016). “Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.” Stat Methods Med Res. ISSN 1477-0334 (Electronic) 0962-2802 (Linking), doi:10.1177/0962280216637093 .